Formulate

Find pharma jobs. Prep for interviews like no one else can.

Browse

Jobs Companies Drugs Indications Career Advisor About

Insider Intel

Intelligence Hub Therapeutic Areas Contribute Intro Network Salary Explorer For Employers Pricing

Legal

argenx Jobs | Formulate

Jobs
argenx

argenx Jobs

Belgium - Zwijnaarde

Biotechnology

argenx is a life sciences company focused on Antibody therapies.

84 open positions at argenx

View Full Profile

Business Leader, Texas (South Texas)

argenx

Posted 3w ago

United States - Field

$204K - $281K

Full-time

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

ImmunologyMID

H-1B · 1 FY23

Business Leader, New York Metro (Pennsylvania)

argenx

Posted 3w ago

United States - Field

$204K - $281K

Full-time

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

ImmunologyMID

H-1B · 1 FY23

Market Head, Northeast

argenx

Posted 3w ago

United States - Field

$236K - $325K

Full-time

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

ImmunologyMID

H-1B · 1 FY23

Business Leader, Texas (North Texas)

argenx

Posted 3w ago

United States - Field

$204K - $281K

Full-time

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

ImmunologyMID

H-1B · 1 FY23

Market Head, South Central

argenx

Posted 3w ago

United States - Field

$236K - $325K

Full-time

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

ImmunologyMID

H-1B · 1 FY23

Senior Director, Portfolio Marketing Community Lead

argenx

Posted 3w ago

Remote

$236K - $325K

Full-time

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

RemoteCommercialNeurologyExecutive

H-1B · 1 FY23

Market Head, Southeast

argenx

Posted 3w ago

United States - Field

$236K - $325K

Full-time

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

ImmunologyMID

H-1B · 1 FY23

Business Leader, Mid-Atlantic (Bluegrass)

argenx

Posted 3w ago

United States - Field

$204K - $281K

Full-time

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

ImmunologyMID

H-1B · 1 FY23

Business Leader, Mid-Atlantic (Mid-Atlantic)

argenx

Posted 3w ago

United States - Field

$204K - $281K

Full-time

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

ImmunologyMID

H-1B · 1 FY23

Business Leader, Great Lakes (Michigan)

argenx

Posted 3w ago

United States - Field

$204K - $281K

Full-time

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

ImmunologyMID

H-1B · 1 FY23

Business Leader, Rocky Plains (Great Plains)

argenx

Posted 3w ago

United States - Field

$204K - $281K

Full-time

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

ImmunologyMID

H-1B · 1 FY23

Market Head, New York Metro

argenx

Posted 3w ago

United States - Field

$236K - $325K

Full-time

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

ImmunologyMID

H-1B · 1 FY23

Market Head, Mid-Atlantic

argenx

Posted 3w ago

United States - Field

Full-time

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

ImmunologyMID

H-1B · 1 FY23

Business Leader, Northwest (Coastal CA)

argenx

Posted 3w ago

United States - Field

$204K - $281K

Full-time

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

ImmunologyMID

H-1B · 1 FY23

Market Head, Florida & Puerto Rico

argenx

Posted 3w ago

United States - Field

$236K - $325K

Full-time

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

ImmunologyMID

H-1B · 1 FY23

Business Leader, Great Lakes (Ohio)

argenx

Posted 3w ago

United States - Field

$204K - $281K

Full-time

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

ImmunologyMID

H-1B · 1 FY23

Business Leader, South Central (Gulf South)

argenx

Posted 3w ago

United States - Field

$204K - $281K

Full-time

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

ImmunologyMID

H-1B · 1 FY23

Market Head, Rocky Plains

argenx

Posted 3w ago

United States - Field

$236K - $325K

Full-time

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

ImmunologyMID

H-1B · 1 FY23

Business Leader, Northeast (Upstate NY & Southern NE)

argenx

Posted 3w ago

United States - Field

$204K - $281K

Full-time

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

ImmunologyMID

H-1B · 1 FY23

Business Leader, New York Metro (New York)

argenx

Posted 3w ago

United States - Field

$204K - $281K

Full-time

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

ImmunologyMID

H-1B · 1 FY23

Company Overview

Active Jobs

Pipeline Programs

Drug Products

Clinical Trials

View Full Company Profile

Therapeutic Areas

Neurology Immunology Oncology

Links

Company Website Careers Page

Hematology

Rare Diseases